This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 code | Q96.0 |
|---|---|
| Special Copayment Reduction code | V021 |
| Re-approval cycle | 5 years |
| Main name (Korean) | Karyotype 45, X |
| Main name (English) | Karyotype 45,X |
| Clinical name | Turner syndrome — classic form (monosomy X) |
| Korean synonyms | Classic Turner syndrome; monosomy X; 45,X karyotype |
|---|---|
| English synonyms | Turner syndrome classic form; Monosomy X; 45,X syndrome; Ullrich-Turner syndrome |
It is not uncommon for 45,X Turner syndrome to go undiagnosed early and to be first diagnosed in adulthood because of primary amenorrhea, infertility or short stature. In adulthood, monitoring for cardiovascular complications (aortic dissection, bicuspid aortic valve, aortic dilation) is a key task directly linked to survival. Continuing estrogen therapy to prevent osteoporosis is important, and counseling and support regarding infertility are also needed. The risk of autoimmune diseases (thyroid disease, inflammatory bowel disease) and diabetes is increased.
The history of Turner syndrome begins in 1938, when Henry H. Turner, an endocrinologist in Oklahoma, USA, described similar symptoms (short stature, sexual infantilism, cubitus valgus, webbed neck) in 7 women and reported them as an endocrine disorder. Turner classified this as a congenital endocrine disease, but its genetic basis was not known at the time.
Similar cases had been reported even before the 1930s. Because Otto Ullrich of Germany had already described a similar case in 1902, it is also called "Ullrich-Turner syndrome" in Europe. In 1959, Charles E. Ford et al. discovered the 45,X karyotype in patients with Turner syndrome through cytogenetic analysis, which was the first proof that a sex chromosome abnormality causes disease in humans. In the same year, Patricia Jacobs et al. confirmed this result, establishing 45,X as the cytogenetic basis of Turner syndrome.
In the 1960s, it was found that mosaic forms (45,X/46,XX, etc.) and structural X abnormalities (isochromosome X, deleted X, ring X) can cause the Turner syndrome phenotype. In the 1970s–80s, clinical research on growth hormone (GH) treatment began actively, and in 1997 the US FDA officially approved GH treatment for Turner syndrome. Since the 2000s, research on gene function by X chromosome location has advanced, and the mechanisms of the phenotype are gradually being elucidated. In 2016, Insul et al. published a study reconfirming that haploinsufficiency of the SHOX (short stature homeobox) gene is the main cause of short stature. In Korea, case reports and research have also gradually increased since the 1970s, and systematic management is currently carried out within the rare disease registration system.
The 45,X karyotype is a state in which only one X chromosome is present and the second sex chromosome (X or Y) is absent. It is one of the most common forms of sex chromosome numerical abnormality.
45,X mostly arises from non-disjunction or chromosome loss during meiosis or early mitosis after fertilization. About 80% are cases in which the paternally derived X or Y chromosome is lost, and the remaining 20% are of maternal origin. This means that 45,X arises mainly from abnormalities in paternal meiosis or early embryonic cell division. Maternal age is not a risk factor for 45,X, and the recurrence risk of germline origin for 45,X is very low.
There is a pure 45,X form in which all cells are 45,X and a mosaic form mixed with normal cells (46,XX, 46,XY). Pure 45,X tends to have the most typical and severe phenotype. The mosaic form may present with a mild or atypical phenotype. Q96.0 corresponds to the pure 45,X karyotype, and the mosaic forms correspond to Q96.3~Q96.8.
The main cause of short stature is haploinsufficiency of the SHOX (short stature homeobox-containing gene) gene located at Xp22.33. Because SHOX is located in the pseudoautosomal region (PAR1) of the X and Y chromosomes and is normally exempt from X inactivation, both alleles are expressed even in normal females (46,XX). In 45,X, only a single SHOX is expressed, resulting in impaired skeletal growth. Haploinsufficiency of genes involved in ovarian development (Xq region) causes premature ovarian insufficiency. For the mechanisms of cardiovascular malformations and lymphedema, the involvement of several genes such as VEGFD and SOS1 has been suggested.
Turner syndrome occurs at a frequency of 1 in 2,000~2,500 female live births. Q96.0 (pure 45,X) accounts for about 40~50% of all Turner syndrome. Remarkably, more than 99% of implanted 45,X embryos are spontaneously aborted (about 7~10% of all spontaneous abortions), so the conception frequency of Turner syndrome is much higher than the birth frequency. It is noteworthy that, because 45,X is mostly lethal in this way, the phenotype of surviving live births may be selected in a particular direction.
In Korea, about 200~300 new cases of Turner syndrome are estimated to occur annually. Diagnosis is made at various ages: some cases are diagnosed prenatally when lymphedema or heart malformations are found on fetal ultrasound, and many are first diagnosed in childhood due to short stature, or in adolescence due to delayed puberty or primary amenorrhea. Some cases remain undiagnosed until adulthood and are first found at infertility clinics. With increased awareness of Turner syndrome and the spread of NIPT, the proportion of prenatal diagnoses has recently been increasing.
The diverse clinical phenotypes of 45,X are explained by haploinsufficiency of X-linked genes. Genes that escape X inactivation play a particularly important role.
The SHOX protein regulates osteoblast differentiation and endochondral ossification. SHOX haploinsufficiency reduces the proliferation and differentiation of growth plate cells, resulting in poor limb growth. In particular, the distal limbs (bone dysplasia of the tibia and radius), cubitus valgus and Madelung's deformity reflect SHOX deficiency. Growth hormone (GH) treatment stimulates growth plate cells through SHOX downstream signaling pathways to induce compensatory growth.
In the fetal period, millions of normal oocytes are formed, but in 45,X they are lost rapidly from the fetal stage. By birth most oocytes have already been lost, and around puberty the ovaries are replaced by fibrous connective tissue strands (streak gonads). Loss of the second copy of ovarian maintenance genes located on the long arm of the X chromosome (Xq) is known to be the main cause of premature ovarian insufficiency, but the specific genes have not yet been fully identified.
Bicuspid aortic valve (BAV) and coarctation of the aorta (CoA) are due to abnormal fetal heart development. Lymphedema results from abnormal fetal lymphatic development; fetal nuchal lymphatic dilation (cystic hygroma) may appear, and neonatal lymphedema, in which the hands and feet are swollen after birth and the swelling resolves within weeks, is typical.
The clinical phenotype of Turner syndrome is highly variable, but typical symptoms are more pronounced when the karyotype is pure 45,X.
On prenatal ultrasound, fetal nuchal cystic hygroma, nonimmune hydrops fetalis, heart malformations and short stature may be found. Lymphedema of hands and feet in the neonatal period and webbed neck (pterygium colli — skin folds at the side of the neck) are signs that strongly suggest Turner syndrome. Congenital heart malformations (bicuspid aortic valve, coarctation of the aorta) may accompany it.
Growth failure is the most prominent symptom; from around age 2 the child is shorter than peers, which parents come to notice. The growth curve shows a typical pattern of growth failure, and short stature progresses even in the absence of growth hormone deficiency. There is a tendency toward recurrent otitis media.
Delayed puberty and primary amenorrhea are the main symptoms. Spontaneous pubertal development may occur in 10~30%, but in most cases natural menstruation is absent or very irregular, with early menopause. Infertility occurs in most (99%), and assisted reproductive technology (IVF with donor eggs) makes pregnancy possible. Social adjustment is mostly normal, but nonverbal learning disabilities, difficulties in learning mathematics and social problems are observed in some.
The characteristic physical signs observed in Turner syndrome, especially the classic 45,X form, are described.
Short stature (mean adult height without treatment: about 142~145 cm for Korean women and about 143~147 cm for Europeans). Shield chest (broad, flat chest), widely spaced nipples and cubitus valgus (elbows bent outward) are typical.
Webbed neck (pterygium colli), low posterior hairline, micrognathia, small mandible and ear abnormalities (low-set ears) are observed.
Bicuspid aortic valve (BAV) is present in 30~50%, and coarctation of the aorta (CoA) in 10~20%. The risk of aortic dilation and aortic dissection increases in adulthood.
Renal malformations such as horseshoe kidney and duplication of the renal pelvis and ureter are present in 30%. Due to premature ovarian insufficiency, the uterus is small and there is no sexual development.
NIPT is effective as a prenatal test for Turner syndrome screening. NIPT detects sex chromosome aneuploidies, including X chromosome monosomy (45,X), relatively sensitively, but because there are false positives and false negatives, invasive confirmatory testing is needed for positive results. If fetal nuchal cystic hygroma, heart malformations, short stature, etc. are found on prenatal ultrasound, prenatal karyotyping is performed. If lymphedema of the hands and feet or webbed neck is present in the neonatal period, karyotyping is needed immediately. In short children with an atypical growth curve, karyotyping or CMA to exclude Turner syndrome should be considered for all girls. Karyotyping must also be performed in women presenting with a chief complaint of delayed puberty or primary amenorrhea.
Turner syndrome is confirmed by cytogenetic testing.
Standard G-banding karyotyping using peripheral blood lymphocytes (analysis of at least 30 cells) is the basic diagnostic test. A sufficient number of cells must be analyzed to increase the sensitivity for detecting mosaic forms. If possible, high-resolution G-banding (850-band level) is used to also check for microdeletions or structural abnormalities.
When CMA is performed in addition to karyotyping, copy number variant (CNV) abnormalities across all chromosomes can be detected simultaneously. It is useful for identifying the origin of a derivative marker chromosome derived from the X chromosome in Turner syndrome.
Y-specific FISH testing is performed to check for the presence of Y chromosome material. It is important when Y material is suspected on karyotyping or when there are clinical signs of virilization. In 45,X/46,XY mosaicism, the presence or absence of Y material is related to the risk of gonadal tumors (germ cell tumors, gonadoblastoma).
FSH/LH (markedly elevated after puberty), estradiol (decreased), anti-Müllerian hormone (AMH, markedly decreased), thyroid function and fasting blood glucose are needed. An OGTT (oral glucose tolerance test) is performed to screen for diabetes and impaired glucose tolerance.
Turner syndrome requires multidisciplinary management of short stature, gonadal insufficiency, cardiovascular malformations and other complications.
GH treatment is the most important medical intervention for treating short stature in Turner syndrome. It is started at an appropriate time (generally after age 2~4, when short stature is confirmed) and continued until the epiphyseal plates close. The earlier treatment is started, the greater the effect, and high doses (0.045~0.050 mg/kg/day) are more effective than standard doses (0.025~0.035 mg/kg/day). The mean gain in final height is 5~8 cm above the height predicted without treatment. IGF-1 levels are monitored to prevent overdosing.
If spontaneous puberty is absent or insufficient, estrogen replacement therapy is started. It is generally started at age 11~12 (12~13 if receiving growth treatment), beginning at a low dose and increasing to the adult dose over 2~3 years. Thereafter, an artificial menstrual cycle is maintained with cyclic combined estrogen and progesterone therapy. Estrogen treatment is essential for skeletal maturation, breast development, uterine growth and maintenance of bone density, and is important for preventing osteoporosis. Continuing hormone replacement therapy until the age of menopause (at least until age 50) is recommended.
For bicuspid aortic valve, worsening of valvular abnormality is followed regularly with echocardiography. If coarctation of the aorta is significant, it is corrected by intervention (balloon dilation) or surgery. Aortic diameter is monitored by MRI, and the aortic diameter/body surface area ratio (Z-score) is tracked; surgery is considered at 3.5~4.0 cm or more. Hypertension is strictly controlled, and cardiovascular risk must be assessed before pregnancy (including donor egg IVF).
In the very few with spontaneous menstruation, fertility preservation may be attempted through ovarian tissue cryopreservation or retrieval of immature oocytes. Donor egg IVF is currently the most realistic method of pregnancy, but the decision must be made carefully after cardiovascular risk assessment.
Life expectancy in Turner syndrome is reported to be shortened by about 10~13 years compared with women in general. The main causes of death are cardiovascular complications (aortic dissection, coronary artery disease). In patients with bicuspid aortic valve, the risk of aortic dissection is about 100 times higher than in the general population, which emphasizes the importance of regular cardiac imaging follow-up. In the absence of cardiovascular malformations, early detection and appropriate management can bring quality of life and life span close to those of women in general. Cognitive function is generally normal, but nonverbal learning, spatial cognition, executive function and mathematical ability may be partly impaired. Psychosocial support is important for quality of life, and emotional support regarding infertility is also needed.
In Turner syndrome, especially the classic 45,X form, the following complications and comorbidities are commonly observed.
Because the recurrence risk of Turner syndrome is very low, special testing of family members is generally unnecessary. However, in 45,X/46,XY mosaicism, the presence of derivative Y material must be checked, and if Y material is present, the risk of gonadal tumors (germ cell tumors, gonadoblastoma) reaches 15~30%, so prophylactic gonadectomy is recommended.
Follow-up management recommendations for adult patients with Turner syndrome: ① annual blood pressure, thyroid function, fasting blood glucose and liver function tests, ② echocardiography and aortic MRI every 2~5 years, ③ hearing tests every 2 years, ④ DXA bone densitometry (after discontinuation of hormone therapy or after age 65), ⑤ continuation of hormone replacement therapy (combined estrogen-progesterone), ⑥ psychosocial support. If pregnancy is desired, donor egg IVF is considered after consultation with a cardiologist, but caution is needed when the aortic diameter is large, because pregnancy itself is a risk factor for aortic dissection.